Cubist Systematic Strategies, LLC Eiger Bio Pharmaceuticals, Inc. Transaction History

Cubist Systematic Strategies, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$0.55 - $1.26 $6,524 - $14,946	11,862 New	11,862 $8,000
Q2 2022 Aug 15, 2022	SELL	$4.99 - $8.96 $123,033 - $220,917	-24,656 Reduced 50.67%	24,003 $151,000
Q1 2022 May 16, 2022	BUY	$3.84 - $9.74 $154,575 - $392,073	40,254 Added 478.93%	48,659 $404,000
Q4 2021 Feb 14, 2022	BUY	$5.12 - $8.19 $43,033 - $68,836	8,405 New	8,405 $44,000
Q2 2020 Aug 14, 2020	SELL	$5.4 - $13.37 $94,294 - $233,466	-17,462 Closed	0 $0
Q1 2020 May 15, 2020	BUY	$4.91 - $14.7 $85,738 - $256,691	17,462 New	17,462 $119,000
Q3 2019 Nov 14, 2019	SELL	$9.59 - $12.0 $162,071 - $202,800	-16,900 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$9.54 - $14.96 $161,226 - $252,824	16,900 New	16,900 $179,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.